Table 5.
Hormonal therapy and prevalence of concurrent endometrial cancer in patients with endometrial hyperplasia.
| Hormonal treatment (−) |
Hormonal treatment (+) |
|||||
|---|---|---|---|---|---|---|
| No. | Concurrent cancer (%) | P-value | No. | Concurrent cancer (%) | P-value | |
| Total | 108 | 29 (26.9%) | 98 | 13 (13.3%) | ||
| Any risk factora | 0.001 | 0.59 | ||||
| None | 2 | 0 | 2 | 0 | ||
| 1 risk factor | 24 | 2 (8.3%) | 33 | 2 (6.1%) | ||
| 2 risk factors | 44 | 8 (18.2%) | 38 | 7 (18.4%) | ||
| 3 risk factors | 33 | 15 (45.5%) | 19 | 3 (15.8%) | ||
| 4 risk factors | 5 | 4 (80%) | 6 | 1 (16.7%) | ||
| Combination patterns | 0.019 | 0.24 | ||||
| Age alone | 15 | 1 (6.7%) | 19 | 1 (5.3%) | ||
| BMI alone | 5 | 1 (20.0%) | 7 | 0 | ||
| DM alone | 1 | 0 | 2 | 0 | ||
| CAH alone | 3 | 0 | 5 | 1 (20.0%) | ||
| Age + BMI | 8 | 1 (12.5%) | 5 | 3 (60.0%) | ||
| Age + DM | 3 | 1 (33.3%) | 2 | 0 | ||
| Age + CAH | 24 | 5 (20.8%) | 13 | 3 (23.1%) | ||
| BMI + DM | 1 | 0 | 4 | 1 (25.0%) | ||
| BMI + CAH | 6 | 1 (16.7%) | 13 | 0 | ||
| DM + CAH | 2 | 0 | 1 | 0 | ||
| Age + BMI + DM | 2 | 0 | 3 | 1 (33.3%) | ||
| Age + BMI + CAH | 16 | 6 (37.5%) | 11 | 2 (18.2%) | ||
| Age + DM + CAH | 12 | 6 (50.0%) | 2 | 0 | ||
| BMI + DM + CAH | 3 | 3 (100%) | 3 | 0 | ||
| Age + BMI + DM + CAH | 5 | 4 (80.0%) | 6 | 1 (16.7%) | ||
Analysis of 206 patients with known information for hormonal treatment for endometrial hyperplasia. Number (%) is shown. Chi-square test for p-values. Significant p-values are emboldened. Abbreviations: No., number; Age, age ≥ 40; BMI, body mass index ≥ 35 kg/m2; DM, diabetes mellitus; and CAH, complex hyperplasia with atypia.
a
Risk factor included: age ≥ 40, BMI ≥ 35 kg/m2, diabetes mellitus, and complex hyperplasia with atypia.